infi-20230829

0001113148-23-000012.txt : 20230901 0001113148-23-000012.hdr.sgml : 20230901 20230901160642 ACCESSION NUMBER: 0001113148-23-000012 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230829 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events FILED AS OF DATE: 20230901 DATE AS OF CHANGE: 20230901 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001113148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330655706 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-31141 FILM NUMBER: 231232525 BUSINESS ADDRESS: STREET 1: 1100 MASSACHUSETTS AVENUE STREET 2: FLOOR 4 CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: 6174531000 MAIL ADDRESS: STREET 1: 1100 MASSACHUSETTS AVENUE STREET 2: FLOOR 4 CITY: CAMBRIDGE STATE: MA ZIP: 02138 FORMER COMPANY: FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/ DATE OF NAME CHANGE: 20060913 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC DATE OF NAME CHANGE: 20000428 8-K 1 infi-20230829.htm 8-K infi-20230829

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 29, 2023

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-31141

33-0655706

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

1100 Massachusetts Avenue, Floor 4, Cambridge, MA

02138

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 453-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

INFI

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.05. Costs Associated with Exit or Disposal Activities.

On July 25, 2023, Infinity Pharmaceuticals, Inc. (the “Company”) announced a plan to reduce ongoing expenditures including a reduction in headcount of 21 positions. Consistent with and in addition to such plan, on August 29, 2023 (the “Termination Date”) the board of directors of the Company (the “Board”) approved a further reduction of 3 positions (the “August Restructuring”), as described in further detail in Items 5.02 and 8.01 below, which are incorporated herein by reference. The August Restructuring is expected to be completed by the end of the third quarter of 2023.

The Company expects to incur a one-time charge in the third quarter of 2023 of approximately $3.9 million in severance and restructuring costs in connection with the August Restructuring, of which approximately $1.6 million will represent cash costs. This charge primarily relates to severance payments, employee benefits and stock-based compensation. The estimates of expenses and cash costs that the Company expects to incur, and the timing thereof, are subject to a number of assumptions and actual results may differ. If the Company subsequently determines that it will incur significant additional expenses or cash costs in connection with the workforce reduction, it will amend this Current Report on Form 8-K to disclose such information.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

As part of the August Restructuring, the Board approved the termination, without cause, of the employment of Adelene Perkins as Chief Executive Officer of the Company, and Robert Ilaria, Jr., M.D., as Chief Medical Officer of the Company, effective September 1, 2023. Ms. Perkins will remain the chair of the Board.

(c)

On August 29, 2023, the Board approved the appointment, effective as of September 1, 2023, of Seth Tasker, J.D., 45, as Chief Executive Officer of the Company. Mr. Tasker has served as the Company’s Senior Vice President, Chief Business Officer since January 2020. Previously, Mr. Tasker served as the Company’s Vice President, General Counsel from July 2016 to January 2020. Mr. Tasker has more than 17 years of experience in the pharmaceutical industry and brings expertise in corporate finance and partnering transactions, corporate governance, securities, compliance, employment law and other legal and operational issues relevant to developing new medicines in both the private and public company setting. Prior to joining the Company in 2008, Mr. Tasker served as associate counsel at Surface Logix, Inc., a privately held biotechnology company focused on developing improved drug therapies addressing Type 2 diabetes, cardiovascular health and oncology. Mr. Tasker received a J.D. and M.B.A from Suffolk University and a B.S. in microbiology from the University of Vermont. Mr. Tasker has no family relationships with any of the Company’s directors or executive officers. In addition, there are no transactions and no proposed transactions between Mr. Tasker and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.

(e)

On September 1, 2023, the Company entered into a severance agreement with Ms. Perkins (the “Perkins Severance Agreement”) in connection with Ms. Perkins’ separation from employment as Chief Executive Officer of the Company. Pursuant to the Company’s Executive Severance Benefits Plan (the “Severance Plan”), Ms. Perkins is entitled to receive a severance payment representing twelve months of base salary and payments for the cost of COBRA over a period of twelve months. However, to reduce severance costs to the Company, Ms. Perkins has agreed to accept, pursuant to the Perkins Severance Agreement: (i) a lump sum payment of $537,876 in severance pay, representing nine months of base salary for Ms. Perkins, reduced from the twelve months of base salary provided for under the Severance Plan, (ii) a lump sum payment of $19,129 representing what would have been the cost of the Company’s COBRA contributions for Ms. Perkins over a period of nine months, reduced from the 12 months as provided for under the Severance Plan, and (iii) immediate vesting of any portion of any outstanding Company equity awards of Ms. Perkins which would have vested within the one (1)-year period following Ms. Perkins’ termination as provided for under the Severance Plan.

Pursuant to the Perkins Severance Agreement, the Company also entered into a consulting agreement (the “Perkins Consulting Agreement”) with Ms. Perkins, effective September 1, 2023, under which Ms. Perkins will continue to provide services to the Company in working to find an alternative path forward for eganelisib following the termination of the Company’s previously announced merger agreement with MEI Pharma, Inc. Pursuant to the terms of the Perkins Consulting Agreement, the Company will pay Ms. Perkins a retention fee of $227,000 (the “Retention Fee”) within 10 days following the effective date of the Perkins Severance Agreement. Fifty percent (50%) of the Retention Fee (the “Perkins Contingent Retention Component”) is subject to and contingent upon Ms. Perkins serving as a consultant and providing services under the Perkins Consulting Agreement for at least forty (40) hours per week if requested by the Company through October 13, 2023, and at least ten (10) hours per week if requested by the Company between October 14, 2023 and December 31, 2023 (the “Retention Date”). If Ms. Perkins fails to provide services specified under the Perkins Consulting Agreement for the minimum hours required through the Retention Date, or Ms. Perkins terminates the Perkins Consulting Agreement prior to the Retention Date (each a “Perkins Consulting Disqualifying Event”), Ms. Perkins will be required to repay to the Company a prorated portion of the Perkins Contingent Retention Component based on the number of days between the Perkins Consulting Disqualifying Event and the Retention Date. In addition, the Company is obligated to pay Ms. Perkins consulting fees at a weekly rate of twenty thousand ($20,000) dollars for her services under the Consulting Agreement through October 13, 2023. Ms. Perkins’ consulting rate will be reduced to a weekly rate of five thousand ($5,000) dollars for her services under the Consulting Agreement from October 14, 2023, until the Retention Date. The Perkins Consulting Agreement may be extended by mutual agreement of the parties, and beginning on September 29, 2023, may be terminated upon five (5) days’ prior written notice by either party.

On September 1, 2023, the Company entered into a severance agreement with Dr. Ilaria (the “Ilaria Severance Agreement”), in connection with Dr. Ilaria’s separation from employment as Chief Medical Officer of the Company. Pursuant to the Severance Plan, Dr. Ilaria is entitled to receive a severance payment representing twelve months of base salary and payments for the cost of COBRA over a period of twelve months. However, to reduce severance costs to the Company, Dr. Ilaria has agreed to accept, pursuant to the Ilaria Severance Agreement: (i) a lump sum payment of $356,362 in severance pay, representing nine months of base salary for Dr. Ilaria reduced from the twelve months of base salary as provided for under the Severance Plan, (ii) a lump sum payment of $27,274 representing what would have been the cost of the Company’s COBRA contributions for Dr. Ilaria over a period of nine months, reduced from the 12 months as provided for under the Severance Plan and (iii) immediate vesting of any portion of any outstanding Company equity awards of Dr. Ilaria which would have vested within the one (1)-year period following Dr. Ilaria’s termination as provided for under the Severance Plan.

Pursuant to the Ilaria Severance Agreement, the Company also entered into a consulting agreement (the “Ilaria Consulting Agreement”) with Dr. Ilaria, effective September 1, 2023,under which Dr. Ilaria will continue to provide services to the Company in working to find an alternative path forward for eganelisib following the termination of the Company’s previously announced merger agreement with MEI Pharma, Inc. Pursuant to the terms of the Ilaria Consulting Agreement, the Company will pay Dr. Ilaria a Retention Fee of $128,000 within 10 days of the effective date of the Ilaria Severance Agreement. Fifty percent (50%) of the Retention Fee (the “Ilaria Contingent Retention Component”) is subject to and contingent upon Dr. Ilaria serving as a consultant and providing services under the Ilaria Consulting Agreement for at least five (5) hours per week if requested by the Company through the Retention Date. If Dr. Ilaria fails to provide services under the Ilaria Consulting Agreement for at least five (5) hours per week, if requested by the Company, through the Retention Date, or if the Ilaria Consulting Agreement is terminated by Dr. Ilaria prior to the Retention Date (each an “Ilaria Consulting Disqualifying Event”), Dr. Ilaria will be required to repay to the Company a prorated portion of the Ilaria Contingent Retention Component based on the number of days between the Ilaria Consulting Disqualifying Event and the Retention Date. In addition, the Company is obligated to pay Dr. Ilaria an hourly consulting fee at a rate of two hundred twenty-eight dollars ($228) per hour for his services under the Consulting Agreement until the Retention Date. The Ilaria Consulting Agreement may be extended by mutual agreement of the parties or earlier terminated upon five (5) days’ prior written notice by either party.

Item 8.01. Other Events.

As part of the August Restructuring, the Board approved the termination, without cause, of the employment of Stephane Peluso, as Chief Scientific Officer of the Company effective as of September 1, 2023.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	INFINITY PHARMACEUTICALS, INC.
Date: September 1, 2023	By:	/s/ Seth A. Tasker

		Chief Executive Officer

EX-101.SCH 2 infi-20230829.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 infi-20230829_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 4 infi-20230829_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Aug. 29, 2023
Cover [Abstract]
Document Type	8-K
Document Period End Date	Aug. 29, 2023
Entity Registrant Name	Infinity Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	000-31141
Entity Tax Identification Number	33-0655706
Entity Address, Address Line One	1100 Massachusetts Avenue
Entity Address, Address Line Two	Floor 4
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02138
City Area Code	617
Local Phone Number	453-1000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	INFI
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Amendment Flag	false
Entity Central Index Key	0001113148

XML 6 infi-20230829_htm.xml IDEA: XBRL DOCUMENT 0001113148 2023-08-29 2023-08-29 false 0001113148 8-K 2023-08-29 Infinity Pharmaceuticals, Inc. DE 000-31141 33-0655706 1100 Massachusetts Avenue Floor 4 Cambridge MA 02138 617 453-1000 false false false false Common Stock, $0.001 par value per share INFI NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.infi.com/role/Cover Cover Cover 1 false false All Reports Book All Reports infi-20230829.htm infi-20230829.xsd infi-20230829_lab.xml infi-20230829_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "infi-20230829.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "infi-20230829.htm" ] }, "labelLink": { "local": [ "infi-20230829_lab.xml" ] }, "presentationLink": { "local": [ "infi-20230829_pre.xml" ] }, "schema": { "local": [ "infi-20230829.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "infi", "nsuri": "http://www.infi.com/20230829", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "infi-20230829.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.infi.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "infi-20230829.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.infi.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001113148-23-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001113148-23-000012-xbrl.zip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end